VoxCell BioInnovation Inc. and adMare BioInnovations have entered a research collaboration focused on assessing the scientific and commercial viability of a novel antibody-based immune-modulating therapy through the use of human-relevant vascularized cancer tissue models. The partnership will combine bioprinted tumor, immune, stromal, and vascular components within a single platform designed for preclinical drug development. The companies said the system enables quantitative evaluation across efficacy and safety endpoints that conventional in vitro and in vivo approaches often fail to capture. VoxCell and adMare said the work aligns with growing regulatory support for alternatives to animal-based testing in biologics development.
The collaboration comes as the U.S. Food and Drug Administration continues expanding the adoption of New Approach Methodologies (NAMs), including organ-on-chip technologies, AI-supported systems, and advanced 3D tissue models aimed at improving the predictive accuracy of preclinical testing. VoxCell’s platform uses a high-resolution bioprinting process capable of producing perfusable vascular networks inside human-like tissue constructs. The models are intended for use in biologics and immune-modulating therapies where endothelial barriers, antibody transport, and immune system interactions influence treatment outcomes.
“adMare’s mission is to translate breakthrough scientific discoveries into strong, investable Canadian life science companies and new therapies that reach patients,” said Matthew J. Carlyle, President and CEO of adMare BioInnovations. “That requires more than capital – it requires hands-on company building support and access to the right commercial R&D tools early on. By integrating VoxCell’s human-relevant vascularized tissue platform into our scientific and commercial validation process we can generate stronger preclinical safety and efficacy evidence sooner. This helps us de-risk innovation, create long-term value, and turn promising science into scalable, globally competitive Canadian companies.”
“Animal models often miss the biology that determines whether a human drug works,” said Dr. Karolina Valente, Chief Executive Officer and Chief Scientific Officer of VoxCell. “Our vascularized tissues bring perfusion, endothelial barriers, immune cells, and stroma into one human-relevant system. Working with adMare on a novel biologic is exactly the use case the FDA had in mind when it called for more predictive, human-relevant tools. The result is better decisions earlier, and fewer animals used along the way.” Data generated through the initiative will support adMare’s program development activities and contribute to efforts aimed at establishing VoxCell’s vascularized cancer tissue model as a reference NAM for immuno-oncology biologics. VoxCell and adMare expect the collaboration to support broader validation of human-relevant testing platforms in oncology research.
